Search the Newsreel

Does Qiagen's Expanded QIAstat-Dx Infection and AMR Menu Reframe the Bull Case for QGEN?

Qiagen recently expanded its QIAstat-Dx platform with new molecular testing capabilities for Cyclospora and a CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel in Europe. These advancements highlight Qiagen's strategy to position QIAstat-Dx as a comprehensive diagnostic tool for infectious diseases and antimicrobial resistance. While …

Qiagen stock trades steadily as molecular diagnostics growth supports margins

Qiagen N.V. (NL0012169213) demonstrates steady stock performance, driven by robust molecular diagnostics demand and efficient cost control. The company's financial health is underpinned by over $2 billion in annual revenue, resilient margins in the mid-to-high twenties percent range, and strong cash flow, which supports …

Capula Management Ltd Purchases New Stake in Qiagen N.V. $QGEN

Capula Management Ltd has acquired a new stake in Qiagen N.V. (NYSE:QGEN) during the first quarter, purchasing 27,820 shares valued at approximately $1,114,000. This comes as other institutional investors like Allspring Global Investments Holdings LLC and Vanguard Group Inc. have also adjusted their holdings …

Qiagen N.V. $QGEN Shares Acquired by Swiss National Bank

The Swiss National Bank significantly increased its holdings in Qiagen N.V. (NYSE:QGEN) by 21.1% in the first quarter, acquiring an additional 124,920 shares. This move is part of broader institutional interest, with several other hedge funds also adjusting their positions in the biotech company. …

Hsbc Holdings PLC Invests $12.92 Million in Qiagen N.V. $QGEN

Hsbc Holdings PLC recently acquired a new stake of 322,819 shares in Qiagen N.V., valued at approximately $12.92 million, representing 0.16% of the company. Other institutional investors have also adjusted their holdings in Qiagen, which has received a consensus "Hold" rating from analysts with …

KKR (KKR) After Qiagen Interest And Allyntra Launch Has Valuation Back In Focus

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. KKR stock in focus after Qiagen interest and medtech platform launch KKR (KKR) is back in the spotlight after reports linked the firm to …

KKR (KKR) Launches Allyntra While Chasing DStelecom And Qiagen

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. KKR (NYSE:KKR) has launched Allyntra, a precision-engineered solutions platform focused on advanced surgical technologies in medical technology. The company is pursuing a controlling stake …

Qiagen stock trades steady as diagnostics demand supports recent earnings

Qiagen's stock is trading steadily following strong Q1 2026 results, which saw revenue increase to $560 million from $510 million the previous year, and adjusted EPS rise to $0.50 from $0.45. The company's performance was driven by consistent demand for molecular diagnostics and life …

William Blair Initiates Qiagen NV(QGEN.US) With Hold Rating

William Blair analyst Matt Larew has initiated coverage on Qiagen NV (QGEN.US) with a 'Hold' rating. Larew has a 54.8% success rate and a 10.1% average return over the past year, according to TipRanks data. The rating reflects an independent third-party analysis and is …

BlackRock Builds Significant Stake in Qiagen, Boosting Institutional Presence

BlackRock, Inc. has significantly increased its stake in Qiagen N.V., now holding a combined capital interest of 12.19% and voting rights of 13.64%. This move, disclosed by the Netherlands Authority for the Financial Markets, highlights growing institutional interest in Qiagen and is expected to …

Allspring Global Investments Holdings LLC Has $100.21 Million Position in Qiagen N.V. $QGEN

Allspring Global Investments Holdings LLC reduced its stake in Qiagen N.V. (NYSE:QGEN) by 21.6% in Q1 2026, valuing its remaining position at $100.21 million. Other institutional investors like Danske Bank A S and Manchester Capital Management LLC also adjusted their holdings. Qiagen recently announced …

Qiagen (QGEN) Investor presentation Summary

Qiagen (QGEN) reported Q1 2026 net sales of $492 million, up 2% actual but down 1% at constant exchange rates (CER), with adjusted diluted EPS at $0.54, meeting expectations. Sample technologies and QIAcuity showed strong growth, while QuantiFERON sales declined due to lower immigration …

QIAGEN Highlights Molecular Testing Solutions Supporting Response to Growing U.S. Cyclospora Outbreak

QIAGEN is providing molecular testing solutions to support the public health response to a growing Cyclospora outbreak in the U.S., with over 1,600 confirmed cases since May 2026. Their FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora infections in about an hour. Additionally, QIAGEN …

Qiagen highlights testing tools amid U.S. cyclosporiasis outbreak

QIAGEN N.V. announced its molecular testing solutions are available to support the U.S. public health response to a recent cyclosporiasis outbreak, which has over 1,600 confirmed cases. The company's QIAstat-Dx Gastrointestinal Panel 2 can detect the parasite, Cyclospora cayetanensis, in about an hour, addressing …

Berenberg Bank Maintains Qiagen NV(QGEN.US) With Hold Rating, Maintains Target Price $45.74

Berenberg Bank has reiterated its Hold rating on Qiagen NV (QGEN.US) and maintained its target price at $45.74. This indicates that the bank believes the stock will perform in line with the market, with limited upside or downside from its current valuation.

QIAGEN N.V. to Release Results for Q2 2026 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) has announced that it will release its second-quarter 2026 financial results shortly after 16:05 New York time on Wednesday, August 5, 2026. A conference call for investors will follow on Thursday, August 6, 2026, at 09:30 …

Over 1,600 U.S. Cyclospora Cases; QIAGEN Test Takes an Hour

QIAGEN (QGEN) has highlighted its molecular testing solutions for the growing number of cyclosporiasis cases in the U.S., with over 1,600 confirmed infections since May 2026. The company's FDA-cleared QIAstat-Dx Gastrointestinal Panel 2 can detect Cyclospora in about an hour as part of a …

1378 Forecast — Price Target — Prediction for 2027

Assessing China Hongqiao Group’s Valuation After Full Year Results And Proposed Final Dividend

China Hongqiao Group (SEHK:1378) Is Up 12.9% After Lifting Its Final Dividend Proposal – Has The Bull Case Changed?

China Hongqiao Group Limited Just Missed Earnings - But Analysts Have Updated Their Models

China Hongqiao Group down more than 12 per cent on weaker-than-expected 2025 earnings

China Hongqiao Group (SEHK:1378) Margin Slippage Challenges Bullish Earnings Growth Narrative

China Hongqiao Group Limited (HKG:1378) Shares Could Be 45% Below Their Intrinsic Value Estimate

Here's Why We Think China Hongqiao Group (HKG:1378) Might Deserve Your Attention Today

China Hongqiao targets US$1.5 billion from share sale in Hong Kong amid aluminium boom

Aluminum Firm China Hongqiao Seeks $1.2 Billion From Shares

Is China Hongqiao Group (HKG:1378) A Risky Investment?

Kangqiao Service Group Limited (2205.HK) stock price, news, quote and history

China Hongqiao Group Limited (1378.HK) income statement

Qian Hu Corporation Limited (BCV.SI) stock price, news, quote and history